Crinetics Pharmaceuticals
CRNX
CRNX was delisted on the 31st of August, 2026.
94 hedge funds and large institutions have $708M invested in Crinetics Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 21 reducing their positions, and 6 closing their positions.
183% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 6
62% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 21
13% more funds holding
Funds holding: 83 → 94 (+11)
7% more capital invested
Capital invested by funds: $661M → $708M (+$46.8M)
0.24% less ownership
Funds ownership: 87.46% → 87.22% (-0.24%)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$19.4M |
| 2 |
FM
Frazier Management
Seattle,
Washington
|
+$17.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$11.9M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$6.24M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$6.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$25.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.5M |
| 3 |
ACM
Altium Capital Management
New York
|
-$7.11M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.4M |
| 5 |
CCM
CAAS Capital Management
New York
|
-$3.13M |
CRNX Hedge Fund Activity: Q3 2021 in Review
94 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q3 2021, worth a combined $708M — up 7.1% from $661M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new CRNX positions and 6 closed out — a net gain of 11 holders — while 34 added to existing stakes and 21 trimmed.
The largest buyer was BVF Inc, adding an estimated $19.4M. The largest seller was Vivo Capital, cutting an estimated $25.8M.
- 94 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q3 2021, up from 83 in Q2 2021.
- Funds reported $708M of Crinetics Pharmaceuticals stock for Q3 2021, up 7.1% quarter-over-quarter.
- 17 funds opened new Crinetics Pharmaceuticals positions in Q3 2021 and 6 closed out, a net change of +11 holders.
- The largest Crinetics Pharmaceuticals buyer in Q3 2021 was BVF Inc, an estimated $19.4M added.
- The largest Crinetics Pharmaceuticals seller in Q3 2021 was Vivo Capital, an estimated $25.8M sold.
Based on aggregated 13F filings for Q3 2021.